CryoPort (CYRX) AI Stock Analysis

• Market Cap: $507.18M
• Dividend Yield: N/A
• Average Volume (3M): 637.66K
• Price to Earnings (P/E): 6.1
• Beta (1Y): 1.30
• Revenue Growth: -10.16%
• EPS Growth: 73.08%
• Country: US
• Employees: 1,090
• Sector: Industrials
• Sector Strength: 72
• Industry: Integrated Freight & Logistics
• EPS (TTM): 2.05
• Shares Outstanding: 50,066,967
• 10 Day Avg. Volume: 703,247
• 30 Day Avg. Volume: 637,665
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.43
• Enterprise Value/Revenue: 1.00
• Enterprise Value/Gross Profit: 2.34
• Enterprise Value/Ebitda: -3.11
• 1Y Price Target: $13.29
• Price Target Upside: 39.02% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 58 Neutral
• Price Target: $11.00 ▲(15.06% Upside)

CryoPort's overall stock score is driven by strong earnings call insights and positive technical indicators, suggesting potential growth and strategic positioning. However, significant financial challenges and valuation concerns weigh down the score. The strategic partnership with DHL and revenue growth provide optimism, but financial instability remains a critical risk.

Positive Factors

Strategic Partnership with DHL

The partnership with DHL enhances CryoPort's global logistics capabilities, particularly in Asia Pacific and EMEA, supporting long-term growth and market expansion.

Revenue Growth in Cell and Gene Therapies

Strong growth in cell and gene therapy revenues indicates CryoPort's effective positioning in a high-demand sector, supporting sustained business expansion.

Product Innovation

Innovative product launches enhance CryoPort's service offerings, improving safety and reliability, which strengthens customer trust and market competitiveness.

Negative Factors

Declining Revenue

The decline in revenue reflects challenges in maintaining market share and demand, which could impact long-term financial health and growth prospects.

Negative Cash Flow

Negative cash flow indicates difficulties in generating sufficient cash from operations, potentially limiting investment in growth and innovation.

Regulatory Challenges

Regulatory setbacks for clients could delay product approvals, affecting CryoPort's revenue streams and market positioning in the life sciences sector.

CryoPort Business Overview & Revenue Model

Company Description

CryoPort, Inc. (CYRX) is a logistics company specializing in temperature-controlled supply chain solutions for the life sciences sector. The company primarily serves the biopharmaceutical, cell and gene therapy, and regenerative medicine industries by providing innovative shipping solutions that ensure the integrity and viability of sensitive biological materials. CryoPort's core products include cryogenic shipping solutions, data monitoring systems, and a range of temperature-controlled packaging options designed to meet the rigorous demands of transporting critical biological samples.

How the Company Makes Money

CryoPort generates revenue through various streams primarily focused on its temperature-controlled shipping solutions. The company earns money by providing specialized packaging and shipping services that cater specifically to the needs of the biopharmaceutical and life sciences industries. Key revenue streams include fees for shipping services, sales of proprietary packaging products, and monitoring services that ensure compliance with regulatory standards. Additionally, CryoPort has established significant partnerships with major biopharmaceutical companies and clinical research organizations, which contribute to its earnings by securing long-term contracts and expanding its service offerings in the rapidly growing market for cell and gene therapies.

CryoPort Financial Statement Overview

Summary

CryoPort faces significant financial challenges across its income statement, balance sheet, and cash flow. Despite a solid gross profit margin, persistent net losses and negative cash flows indicate operational inefficiencies and financial instability. The improvement in leverage metrics provides some positive outlook, but overall, CryoPort needs to address its profitability and cash management to achieve sustainable growth and financial health.

Income Statement

CryoPort's income statement reflects significant challenges. The company has experienced declining revenues from $237.3 million in 2022 to $214.8 million in the TTM period ending March 2025. Despite a healthy gross profit margin of approximately 42.9% in TTM, the company struggles with negative EBIT and net income margins, indicating consistent operating and net losses. The TTM net profit margin is -50.2%, a deterioration from -15.7% in 2022, highlighting worsening profitability.

Balance Sheet

CryoPort's balance sheet shows mixed signals. The debt-to-equity ratio has improved slightly to 0.61 in TTM from 0.78 in 2022, indicating a reduction in leverage, but the company's equity ratio has decreased to 57.0%, reflecting reduced equity relative to assets. The return on equity remains negative due to ongoing losses, with a TTM ROE of approximately -27.0%. The balance sheet displays adequate liquidity with $244 million in cash and short-term investments, though overall financial stability is challenged by recurring losses.

Cash Flow

CryoPort's cash flow statement is concerning, with negative operating and free cash flows. The TTM operating cash flow is -$17.4 million, further stressing financial operations. Free cash flow is also negative at -$34.4 million, indicating insufficient cash generation to cover capital expenditures. The free cash flow to net income ratio remains below 1, demonstrating cash flow struggles in tandem with net losses.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	214.83M	228.38M	233.25M	237.28M	222.61M	78.70M
Gross Profit	92.20M	99.63M	99.33M	103.87M	96.58M	36.33M
EBITDA	-69.31M	-78.61M	-66.36M	-6.19M	-248.91M	-20.31M
Net Income	-107.84M	-114.76M	-99.59M	-37.33M	-275.53M	-32.69M
Balance Sheet
Total Assets	699.84M	703.49M	957.74M	1.04B	1.11B	552.40M
Cash, Cash Equivalents and Short-Term Investments	244.03M	261.75M	456.75M	523.32M	628.80M	93.32M
Total Debt	242.67M	250.70M	416.00M	435.91M	427.06M	130.92M
Total Liabilities	301.03M	301.59M	468.72M	482.91M	471.14M	169.71M
Stockholders Equity	398.81M	401.90M	489.02M	555.84M	641.83M	382.70M
Cash Flow
Free Cash Flow	-34.39M	-33.58M	-45.66M	-26.05M	-16.88M	-24.54M
Operating Cash Flow	-17.40M	-16.32M	-757.00K	-1.85M	8.13M	-14.87M
Investing Cash Flow	176.29M	176.81M	36.05M	-59.68M	-469.25M	-382.31M
Financing Cash Flow	-162.23M	-161.53M	-23.80M	-39.17M	564.34M	385.58M

CryoPort Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.56
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 9.56 is above the 20-day moving average (MA) of 9.33, above the 50-day MA of 8.53, and above the 200-day MA of 7.21, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 54.68 is Neutral, neither overbought nor oversold. The STOCH value of 68.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLGT	64 Neutral	288.04M	17.24	―	―	12.49%	125.41%
CYRX	58 Neutral	$507.18M	6.07	-8.50%	―	-10.16%	73.08%
AIRT	55 Neutral	64.10M	-8.58	-140.61%	―	5.14%	-17.39%
CRGO	55 Neutral	163.64M	-7.57	-40.98%	―	21.92%	-4.84%
FLX	47 Neutral	228.33M	-6.16	-19.61%	―	-10.97%	-696.45%
FWRD	44 Neutral	853.55M	-4.66	-114.00%	―	30.12%	79.23%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%

CryoPort Corporate Events

CryoPort Sells CRYOPDP Business to DHL Group

On June 11, 2025, Cryoport, Inc. completed the divestiture of its CRYOPDP Business to DHL Group for approximately $200 million, as part of a strategic move to enhance its core capabilities and focus on the rapidly growing regenerative medicine market. This transaction, along with a newly formed strategic partnership with DHL, is expected to strengthen Cryoport’s positioning in the Asia Pacific and EMEA regions, offering enhanced supply chain services and contributing to the company’s long-term profitability goals.

CryoPort Holds 2025 Annual Stockholders Meeting

On June 6, 2025, Cryoport, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The election of directors resulted in the appointment of six individuals to serve until the 2026 Annual Meeting. Additionally, the appointment of Deloitte and Touche LLP as the independent registered public accounting firm was ratified. Stockholders also approved the compensation of the company’s named executive officers and decided to hold an advisory vote on this compensation annually.